FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Frohlich Tom (Last) (First) (Middle)					2. Issuer Name and Ticker or Trading Symbol CHINOOK THERAPEUTICS, INC. [KDNY]							5. Relationship of Reporting Pe Check all applicable) Director X Officer (give title below)			10% Owner Other (specify below)			
C/O CHINOOK THERAPEUTICS, INC. 400 FAIRVIEW AVE. NO., 9TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 01/31/2022							(Chief Oper	rating	Officer			
(Street) SEATTL	E W	/A	98102		4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Lir	e) X Form Form					
(Oity)	(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				2A. Deemed Execution Date,		3. 4. Secu Transaction Dispose		4. Securi	rities Acquired (A) ed Of (D) (Instr. 3, 4		5. Amou Securiti Benefic	int of es ally Following	Form	: Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D) Pri		Transac (Instr. 3	tion(s)			(III3ti. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	nsaction de (Instr.	Derivative Securities Acquired or Dispo	Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price o Derivative Security (Instr. 5)		e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	de V	(A)	(D)	Date Exercisable		piration ate	Title	Amount or Number of Share	unt (In ber		ion(s)			
Stock Option (right to buy)	\$12.9	01/31/2022		I		100,000		(1)	01	/30/2032	Common Stock	100,00	\$0.00	100,0	00	D		
Restricted Stock (RSU) (Common Stock)	(2)	01/31/2022		I		25,000		(3)	01	/31/2025	Common Stock	25,000	\$0.00	25,00	00	D		

Explanation of Responses:

- 1. The stock option vests as to 25% of the total shares on January 31, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- $2.\ Each\ RSU\ represents\ a\ contingent\ right\ to\ receive\ one\ (1)\ share\ of\ the\ Issuer's\ Common\ Stock\ upon\ settlement.$
- 3. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.

Remarks:

/s/ Kirk Schumacher, Attorneyin-Fact

02/02/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.